Look­ing to grow block­buster Po­m­a­lyst fran­chise, Cel­gene de­clares a win for mul­ti­ple myelo­ma triplet in piv­otal PhI­II

Re­searchers for Cel­gene say that they hit the pri­ma­ry end­point for OP­TI­MIS­MM, a piv­otal Phase III for treat­ment-re­sis­tant mul­ti­ple myelo­ma that com­bined Po­m­a­lyst with borte­zomib …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.